Martijn D. Steenwijk

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

Enhancing the interpretability of spinal cord atrophy in multiple sclerosis by reducing interindividual variability due to anatomical differences.

Enhancing the interpretability of spinal cord atrophy in multiple sclerosis by reducing interindividual variability due to anatomical differences.

Journal: Multiple sclerosis and related disorders
Published: November 11, 2025

Quantifying cortical lesions in multiple sclerosis MRI datasets using multi-contrast post-processing and deep learning.

Quantifying cortical lesions in multiple sclerosis MRI datasets using multi-contrast post-processing and deep learning.

Journal: Communications medicine
Published: March 31, 2025

Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.

Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 26, 2025

In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis.

In vivo evidence for cell body loss in cortical lesions in people with multiple sclerosis.

Journal: Annals of clinical and translational neurology
Published: September 28, 2024

Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.

Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.

Journal: Annals of clinical and translational neurology
Published: August 15, 2024

Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.

Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 14, 2024

Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.

Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 18, 2024

Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.

Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.

Journal: Multiple sclerosis and related disorders
Published: November 29, 2023

Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.

Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.

Journal: Journal of neurology
Published: September 22, 2023

Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.

Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.

Journal: Journal of neurology
Published: May 29, 2023

Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection.

Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection.

Journal: Radiology
Published: February 07, 2023

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 05, 2022
Showing 1-12 of 79

Last Updated: 09/26/2026